Translate this page into:
Solitary Metastasis of Prostatic Adenocarcinoma to the Testicle Detected by 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography
Address for correspondence: Dr. Mohamad Haidar, Department of Diagnostic Radiology, American University of Beirut Medical Center, PO Box: 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon. E-mail: mh209@aub.edu.lb
-
Received: ,
Accepted: ,
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
We present a case of a 79-year-old man with prostate cancer with biochemical recurrence after radical prostatectomy and hormonal therapy. 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) was performed to look for recurrent disease, and a solitary metastasis to the left testicle was detected. This case report highlights the importance of 68Ga-PSMA PET/CT in detecting unusual metastatic lesions from prostate cancer in patients with biochemical recurrence.
Keywords
68Ga-prostate-specific membrane antigen
positron emission tomography/computed tomography
prostate cancer
testicular metastasis
Introduction
68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has proved superiority compared to other modalities; both regarding sensitivity and specificity for detecting lesions in patients with a biochemically recurrent prostate cancer,[1] this, in turn, has prompted a significant change in management of these patients.[2]
Case Report
We present a case of a 79-year-old man with prostate cancer who initially presented with prostate-specific antigen (PSA) level of 7 ng/ml, suspicious digital rectal examination, and positive transrectal ultrasound biopsy. The patient underwent radical prostatectomy 17 years ago, and histopathologic evaluation showed Gleason's score 7 (4 + 3) adenocarcinoma. PSA level had dropped following surgery to 0.02 ng/mL, and the patient was maintained on hormonal therapy with triptorelin.
The patient presented with rising PSA levels from 0.47 ng/ml to 3.9 ng/ml in a span of 3 months, in keeping with biochemical recurrence.
68Ga-PSMA PET/CT was performed and showed a single abnormal radiotracer-avid focal area localized to the left testicle with maximum standardized uptake value 9.3, and a concern for metastasis was raised [Figure 1]. This was further evaluated with ultrasound and magnetic resonance imaging examinations, confirming the presence of focal lesion [Figure 2].


The patient underwent bilateral orchiectomy, and histopathologic evaluation revealed metastatic prostatic adenocarcinoma to the left testicle.
Discussion
Metastatic disease to testicles from solid tumors is very rare; a retrospective autopsy study of 738 patients with solid malignant neoplasms found metastasis to testicles in 0.68% of patients.[3] Prostate cancer is the most common culprit, which was found in 35.4% of these patients as per Haupt et al.[4]
Excluding autopsy cases and incidental tumors in therapeutic orchiectomies, metastatic carcinomas to the testicles are usually solitary and unilateral, which may simulate primary neoplasms.[5]
Prolongation of the course of prostate cancer due to progressive hormonal therapies may have increased the incidence of metastatic disease to the testicles because they have more time to develop.[6]
To the best of our knowledge, there are only two cases of solitary metastatic prostate cancer to the testicle diagnosed by 68Ga-PSMA PET/CT and reported in the literature.[78]
This case report highlights the importance of 68Ga-PSMA PET/CT in detecting unusual metastatic lesions from prostate cancer in patients with biochemical recurrence.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol. 2016;70:926-37.
- [Google Scholar]
- Impact of 68GA-PSMA PET/CT on treatment of patients with recurrent/metastatic high risk prostate cancer-A multicenter study. Int Braz J Urol. 2018;44:892-9.
- [Google Scholar]
- Testicular metastases from solid tumors: An autopsy study. Ann Diagn Pathol. 2000;4:59-64.
- [Google Scholar]
- Metastatic carcinoma involving the testis. Clinical and pathologic distinction from primary testicular neoplasms. Cancer. 1984;54:709-14.
- [Google Scholar]
- Metastatic carcinoma to the testis: A clinicopathologic analysis of 26 nonincidental cases with emphasis on deceptive features. Am J Surg Pathol. 2008;32:1683-93.
- [Google Scholar]
- Early detection of bilateral testicular metastases from prostatic adenocarcinoma using 68Ga-PSMA ligand PET/CT. Clin Nucl Med. 2017;42:563-4.
- [Google Scholar]
- Solitary testicular metastasis from prostate cancer. A case report diagnosed by PET/CT with PSMA. Eur J Nucl Med Mol Imaging. 2018;45:888-9.
- [Google Scholar]
